--- title: "Popular pre-market trades in the US stock market: Pyxis Oncology up 9.97% in pre-market; Aehr Test up 8.27% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/295924938.md" description: "Pyxis Oncology pre-market up 9.97%; Aehr Test pre-market up 8.27%; Microbus pre-market up 177.84%; Capricor Therapeutics pre-market up 113.58%; Akanda pre-market up 73.90%" datetime: "2026-08-14T11:09:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295924938.md) - [en](https://longbridge.com/en/news/295924938.md) - [zh-HK](https://longbridge.com/zh-HK/news/295924938.md) generator: "portal-rs" --- # Popular pre-market trades in the US stock market: Pyxis Oncology up 9.97% in pre-market; Aehr Test up 8.27% in pre-market **Pre-market Hot Trades in US Stocks** Pyxis Oncology is up 9.97% in pre-market trading. Based on recent key news: 1. On August 13, Pyxis Oncology announced its second-quarter financial report, reporting a loss of $0.40 per share, exceeding analysts' expectations of $0.35, leading to a pre-market drop of 1.5%. The company did not report any milestone revenue, compared to $2.8 million in the same period last year. Administrative expenses increased from $5.4 million to $9.9 million, primarily due to severance pay and increased stock compensation. Source: Reuters 2. On August 14, the market expressed concerns about a potential equity sale by Pyxis Oncology, which could put pressure on the trading price and affect the company's ability to obtain favorable conditions in the capital markets. Wall Street's consensus rating for PYXS stock is a strong buy, based on 7 buys and 1 hold. Source: MarketBeat 3. On August 13, analysts rated Pyxis Oncology as a buy, with an average 12-month target price of $7, approximately 54.6% higher than the recent closing price of $3.18. Source: LSEG Data The biotechnology industry has shown recent performance volatility and requires attention. Aehr Test Systems is up 8.27% in pre-market trading. Based on recent key news: 1. On August 12, Aehr Test Systems announced it received a $22 million follow-on production order from its major AI processor customer, supporting the customer's expansion of production capacity, driving the stock price up about 5%. 2. On August 13, Aehr Test Systems' stock price rose 12% to $131.60, increasing more than sixfold since the beginning of the year, with orders supporting the customer's expansion of production capacity. 3. On August 12, Aehr Test Systems CEO Gayn Erickson sold 40,000 shares of company stock, totaling $5.2337 million. The semiconductor industry is experiencing strong demand, and the AI market is growing rapidly. **Top Gainers in Pre-market US Stocks** WeBus is up 177.84% in pre-market trading. Based on recent key news: 1. On August 10, Wetour Robotics Ltd. released important information through the EDGAR system, showing significant progress in technological innovation. This news boosted market confidence in its future growth potential, driving the stock price significantly higher. Source: EDGAR 2. On August 11, market tolerance for traditional business models decreased, and investors became cautious towards companies that failed to achieve digital integration. Although this article did not provide investment advice, it reflects the market's emphasis on innovation and digital transformation. Source: Public Technologies 3. No other significant news recently. The market emphasizes innovation and digital transformation Capricor Therapeutics pre-market rose 113.58%. Based on recent key news: 4. On August 14, Capricor Therapeutics announced that the U.S. FDA agreed to review new data for its Duchenne muscular dystrophy treatment drug deramiocel. This move was seen by analysts as a positive signal reducing regulatory risk, driving the stock price up by 116.9%. Source: Reuters 5. On August 14, Capricor Therapeutics reported a net loss of $40.7 million for the second quarter. Despite the poor financial performance, market optimism regarding the FDA review offset the negative impact. Source: Reuters 6. On August 14, Capricor Therapeutics stated that it is adjusting its commercial launch expenditures while awaiting regulatory clarity, indicating the company's cautious approach to capital management. Source: Reuters The biotechnology industry has recently faced regulatory challenges. Akanda pre-market rose 73.90%. Based on recent key news: 1. On August 13, Akanda Corporation released its latest financial report, showing that the company's stock price has fallen by 94.80% over the past 12 months, currently close to its annual low. Nevertheless, pre-market trading showed a significant rise in stock price, possibly due to a market reassessment of its future growth potential. Source: Newsfile 2. On August 14, Benzinga Pro data showed that Akanda's Relative Strength Index (RSI) was 29.27, indicating that the stock is in an oversold state, which may have attracted bottom-fishing buyers. Source: Benzinga 3. On August 14, FTF Company announced updates on its 28 active cellular tower sites, marking an important step towards sustained revenue growth. Although not directly related to Akanda, positive news within the industry may impact market sentiment. Source: Benzinga Market sentiment is positive, with significant capital inflow, but caution is needed regarding volatility risks ### Related Stocks - [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md) - [AEHR.US](https://longbridge.com/en/quote/AEHR.US.md) - [WETO.US](https://longbridge.com/en/quote/WETO.US.md) - [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md) - [AKAN.US](https://longbridge.com/en/quote/AKAN.US.md) ## Related News & Research - [Alberto Salamone Sells 9,672 Shares of Aehr Test Systems (NASDAQ:AEHR) Stock](https://longbridge.com/en/news/295999325.md) - [Is Aehr Test Systems (AEHR) Overvalued As Its Share Price Momentum Surges?](https://longbridge.com/en/news/296172405.md) - [Aehr Test Systems Exec VP Sales & Mktg Vernon Rogers disposes of common shares worth $715,010.38](https://longbridge.com/en/news/296258063.md) - [Aehr Test Systems EVP, Ppbi Business Sold Shares Worth Over $1.2M](https://longbridge.com/en/news/295965579.md) - [Aehr Test Systems director Laura Oliphant sells 1,717 common shares worth $228,361](https://longbridge.com/en/news/295847864.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**